# A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

> **NCT04439526** · — · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 356 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT04439526
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-10
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439526, "A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04439526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*